StatOrigin open statistical archive
Industries Indicators Regions Rankings Compare Sources

Roche

53 data points extracted from 3 publications by this organisation.

Cite & reuse Official site Get this data as JSON
Data points
53
Documents
3
Indicators
35
Regions
8
Publisher type
Company

Bibliography

Documents used

Every publication we have taken a number from, with the date we read it and the link status at that time.

Document Type Published Retrieved Link Data points
U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments Licence: See source Press release 10 Sep 2026 15 Sep 2026 Reachable 2
Roche’s US subsidiary Genentech announces manufacturing expansion in the United States Licence: See source Press release 20 Aug 2026 15 Sep 2026 Reachable 8
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a... Licence: See source Press release 23 Jul 2026 15 Sep 2026 Reachable 43

Every figure

Data points

Every figure taken from this organisation, grouped by indicator.

53 data points across 35 indicators.
IndicatorRegionPeriodValueTypeFull record
Company countries of operationGlobalas of 20 Aug 2026150actual →
Company operating locationsUnited Statesas of 20 Aug 202624actual →
Core diluted earnings per shareGlobalQ1 202610.8 CHFactual →
Core diluted earnings per shareGlobalQ1 202511.1 CHFactual →
Core diluted earnings per share growth at constant exchange ratesGlobalQ1 20269%actual →
Core diluted earnings per share growth in Swiss francsGlobalQ1 2026-2%actual →
Core earnings per share growth at constant exchange ratesGlobalQ1 20269%actual →
Core earnings per share growth in Swiss francsGlobalQ1 2026-2%actual →
Core operating profitGlobalQ1 202611.9 billion CHFactual →
Core operating profitGlobalQ1 202512,010 million CHFactual →
Core operating profit (half year)Globalas of 30 Jun 202611,856 million CHFactual →
Core operating profit growth at constant exchange ratesGlobalQ1 202610%actual →
Core operating profit growth in Swiss francsGlobalQ1 2026-1%actual →
Countries with drug approvalGlobalas of 10 Sep 202690actual →
Group salesGlobalQ1 202630.4 billion CHFactual →
Group sales growth at constant exchange ratesGlobalQ1 20266%actual →
Group sales growth in Swiss francsGlobalQ1 2026-2%actual →
Group sales growth in US dollarsGlobalQ1 20268%actual →
IFRS diluted earnings per share growth in Swiss francsGlobalQ1 2026-8%actual →
IFRS operating profitGlobalQ1 20269.7 billion CHFactual →
IFRS operating profitGlobalQ1 202510,330 million CHFactual →
IFRS operating profit (half year)Globalas of 30 Jun 20269,671 million CHFactual →
IFRS operating profit growth at constant exchange ratesGlobalQ1 20266%actual →
IFRS operating profit growth in Swiss francsGlobalQ1 2026-6%actual →
Off-patent products salesGlobalQ1 20262.6 billion CHFactual →
Patients treated with drugGlobalas of 10 Sep 202610,000actual →
Pharmaceutical corporate employmentUnited Statesas of 20 Aug 202625,000estimate →
Pharmaceutical manufacturing employment creationUnited Statesas of 20 Aug 2026250forecast →
Pharmaceutical manufacturing employment creationUnited Statesend of 2031250forecast →
Pharmaceutical manufacturing facility capital investmentUnited Statesas of 20 Aug 2026750 million USDforecast →
Pharmaceutical manufacturing sitesUnited Statesas of 20 Aug 202613actual →
Pharmaceutical research and development sitesUnited Statesas of 20 Aug 202615actual →
Pharmaceuticals division salesGlobalQ1 202623.6 billion CHFactual →
Pharmaceuticals division sales growth at constant exchange ratesGlobalQ1 20266%actual →
Pharmaceuticals division sales growth in Swiss francsGlobalQ1 2026-1%actual →
Pharmaceuticals division sales growth in US dollarsGlobalQ1 20268%actual →
Sales growth at constant exchange ratesGlobalQ1 20263%actual →
Sales growth at constant exchange ratesEuropean UnionQ1 20261%actual →
Sales growth at constant exchange ratesAsia-PacificQ1 2026-5%actual →
Sales growth at constant exchange ratesLatin America and the CaribbeanQ1 202610%actual →
Sales growth at constant exchange ratesNorth AmericaQ1 20268%actual →
Sales growth at constant exchange ratesChinaQ1 2026-9%actual →
Sales growth at constant exchange ratesJapanQ1 202611%actual →
Sales growth at constant exchange ratesUnited StatesQ1 20266%actual →
Sales growth in Swiss francsGlobalQ1 2026-1%actual →
Sales growth in Swiss francsEuropean UnionQ1 2026-1%actual →
Sales growth in Swiss francsAsia-PacificQ1 2026-12%actual →
Sales growth in Swiss francsLatin America and the CaribbeanQ1 20265%actual →
Sales growth in Swiss francsNorth AmericaQ1 2026-1%actual →
Sales growth in Swiss francsChinaQ1 2026-12%actual →
Sales growth in Swiss francsJapanQ1 2026-5%actual →
Sales growth in Swiss francsUnited StatesQ1 2026-3%actual →
Top growth drivers salesGlobalQ1 202611 billion CHFactual →

Cite & reuse

Cite this page

Data on this page is published under CC BY 4.0. Credit Roche as the original publisher; each record page carries its own citation.

Roche. Retrieved from StatOrigin: https://statorigin.org/sources/roche

This organisation as JSON

Keep exploring

Related

Industries using this source

Go further

Last verified 17 September 2026. Link status is rechecked weekly.